Lopinavir/Ritonavir Mylan

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
20-12-2019
Produktens egenskaper Produktens egenskaper (SPC)
20-12-2019

Aktiva substanser:

lopinavir/ritonavir

Tillgänglig från:

Mylan S.A.S.

ATC-kod:

J05AR10

INN (International namn):

lopinavir/ritonavir

Terapeutisk grupp:

Antivirals for systemic use,

Terapiområde:

HIV Infections

Terapeutiska indikationer:

Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

Produktsammanfattning:

Revision: 9

Bemyndigande status:

Authorised

Tillstånd datum:

2016-01-14

Bipacksedel

                                67
B. PACKAGE LEAFLET
68
PACKAGE LEAFLET: INFORMATION FOR THE USER
LOPINAVIR/RITONAVIR MYLAN 200 MG/50 MG FILM-COATED TABLETS
lopinavir/ritonavir
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU OR YOUR CHILD.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you or your child only. Do not
pass it on to others. It may harm
them, even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Lopinavir/Ritonavir Mylan is and what it is used for
2.
What you need to know before you or your child takes
Lopinavir/Ritonavir Mylan
3.
How to take Lopinavir/Ritonavir Mylan
4.
Possible side effects
5.
How to store Lopinavir/Ritonavir Mylan
6.
Contents of the pack and other information
1.
WHAT LOPINAVIR/RITONAVIR MYLAN IS AND WHAT IT IS USED FOR
-
Your doctor has prescribed lopinavir/ritonavir to help to control your
Human Immunodeficiency Virus
(HIV) infection. Lopinavir/ritonavir does this by slowing down the
spread of the infection in your
body.
-
Lopinavir/Ritonavir Mylan is not a cure for HIV infection or AIDS
-
Lopinavir/ritonavir is used by children 2 years of age or older,
adolescents and adults who are infected
with HIV, the virus which causes AIDS.
-
Lopinavir/Ritonavir Mylan contains the active substances lopinavir and
ritonavir. Lopinavir/ritonavir
is an antiretroviral medicine. It belongs to a group of medicines
called protease inhibitors.
-
Lopinavir/ritonavir is prescribed for use in combination with other
antiviral medicines. Your doctor
will discuss with you and determine which medicines are best for you.
2.
WHAT YOU NEED TO KNOW BEFORE YOU OR YOUR CHILD TAKES
LOPINAVIR/RITONAVIR MYLAN
_ _
DO NOT TAKE LOPINAVIR/RITONAVIR MYLAN IF:
-
you are allergic to lopina
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets.
Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets
Each film-coated tablet contains 100 mg of lopinavir co-formulated
with 25 mg of ritonavir as a
pharmacokinetic enhancer.
Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets
Each film-coated tablet contains 200 mg of lopinavir co-formulated
with 50 mg of ritonavir as a
pharmacokinetic enhancer.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets
Approx 15.0 mm x 8.0 mm, white, film coated, ovaloid, biconvex beveled
edge tablet debossed with 'MLR4'
on one side of the tablet and plain on the other side.
Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets
Approx 18.8 mm x 10.0 mm, white, film coated, ovaloid, biconvex
beveled edge tablet debossed with
'MLR3' on one side of the tablet and plain on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Lopinavir/ritonavir is indicated in combination with other
antiretroviral medicinal products for the treatment
of human immunodeficiency virus (HIV-1) infected adults, adolescents
and children above the age of
2 years.
The choice of lopinavir/ritonavir to treat protease inhibitor
experienced HIV-1 infected patients should be
based on individual viral resistance testing and treatment history of
patients (see sections 4.4 and 5.1).
_ _
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Lopinavir/ritonavir should be prescribed by physicians who are
experienced in the treatment of HIV
infection.
Lopinavir/ritonavir tablets must be swallowed whole and not chewed,
broken or crushed.
Posology
_Adults and adolescents _
The standard recommended dosage of lopinavir/ritonavir tablets is
400/100 mg (two 200/50 mg) tablets
twice daily taken with or without food. In adul
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 30-01-2024
Produktens egenskaper Produktens egenskaper bulgariska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 09-02-2016
Bipacksedel Bipacksedel spanska 30-01-2024
Produktens egenskaper Produktens egenskaper spanska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 09-02-2016
Bipacksedel Bipacksedel tjeckiska 30-01-2024
Produktens egenskaper Produktens egenskaper tjeckiska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 09-02-2016
Bipacksedel Bipacksedel danska 30-01-2024
Produktens egenskaper Produktens egenskaper danska 30-01-2024
Bipacksedel Bipacksedel tyska 30-01-2024
Produktens egenskaper Produktens egenskaper tyska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 09-02-2016
Bipacksedel Bipacksedel estniska 30-01-2024
Produktens egenskaper Produktens egenskaper estniska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 09-02-2016
Bipacksedel Bipacksedel grekiska 30-01-2024
Produktens egenskaper Produktens egenskaper grekiska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 09-02-2016
Bipacksedel Bipacksedel franska 30-01-2024
Produktens egenskaper Produktens egenskaper franska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 09-02-2016
Bipacksedel Bipacksedel italienska 30-01-2024
Produktens egenskaper Produktens egenskaper italienska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 09-02-2016
Bipacksedel Bipacksedel lettiska 30-01-2024
Produktens egenskaper Produktens egenskaper lettiska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 09-02-2016
Bipacksedel Bipacksedel litauiska 30-01-2024
Produktens egenskaper Produktens egenskaper litauiska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 09-02-2016
Bipacksedel Bipacksedel ungerska 30-01-2024
Produktens egenskaper Produktens egenskaper ungerska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 09-02-2016
Bipacksedel Bipacksedel maltesiska 30-01-2024
Produktens egenskaper Produktens egenskaper maltesiska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 09-02-2016
Bipacksedel Bipacksedel nederländska 30-01-2024
Produktens egenskaper Produktens egenskaper nederländska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 09-02-2016
Bipacksedel Bipacksedel polska 30-01-2024
Produktens egenskaper Produktens egenskaper polska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 09-02-2016
Bipacksedel Bipacksedel portugisiska 30-01-2024
Produktens egenskaper Produktens egenskaper portugisiska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 09-02-2016
Bipacksedel Bipacksedel rumänska 30-01-2024
Produktens egenskaper Produktens egenskaper rumänska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 09-02-2016
Bipacksedel Bipacksedel slovakiska 30-01-2024
Produktens egenskaper Produktens egenskaper slovakiska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 09-02-2016
Bipacksedel Bipacksedel slovenska 30-01-2024
Produktens egenskaper Produktens egenskaper slovenska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 09-02-2016
Bipacksedel Bipacksedel finska 30-01-2024
Produktens egenskaper Produktens egenskaper finska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 09-02-2016
Bipacksedel Bipacksedel svenska 30-01-2024
Produktens egenskaper Produktens egenskaper svenska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 09-02-2016
Bipacksedel Bipacksedel norska 30-01-2024
Produktens egenskaper Produktens egenskaper norska 30-01-2024
Bipacksedel Bipacksedel isländska 30-01-2024
Produktens egenskaper Produktens egenskaper isländska 30-01-2024
Bipacksedel Bipacksedel kroatiska 30-01-2024
Produktens egenskaper Produktens egenskaper kroatiska 30-01-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 09-02-2016

Sök varningar relaterade till denna produkt